What's new? Log in Free sign up

Cumberland Pharmaceuticals (CPIX)

Company Profile

Company profile

Ticker

CPIX

Exchange

Website

www.cumberlandpharma.com

CEO

A. J. Kazimi MBA

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • AbbVie • Teva Pharmaceutical Industries Limited • Bausch Health Companies • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

AppTech Corp., CSI Business Finance, Inc., HEALTH EXPRESS USA INC, Natural Nutrition Inc.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

CPIX stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Entry into a Material Definitive Agreement

Quarterly report

7 Nov 25

Cumberland Pharmaceuticals Reports 12% Year-to-date Revenue Growth

Cumberland Pharmaceuticals Announces the Addition of an

Quarterly report

8 Aug 25

Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date

Quarterly report

9 May 25

Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

Submission of Matters to a Vote of Security Holders

FIGHT DMD Trial Results

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Kenneth Krogulski

Kenneth Krogulski

Cumberland Pharmaceuticals Inc

Financial summary

Financial statements Chart CPIX financial data

Quarter (USD)	Sep 25	Jun 25	Mar 25	Dec 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	15.20 mm	15.20 mm	15.20 mm	15.20 mm	15.20 mm	15.20 mm
Cash burn (monthly)	296.85 k	189.00 k	655.09 k	281.62 k	(no burn)	(no burn)
Cash used (since last report)	668.96 k	425.93 k	1.48 mm	634.65 k	n/a	n/a
Cash remaining	14.53 mm	14.77 mm	13.72 mm	14.56 mm	n/a	n/a
Runway (months of cash)	48.9	78.2	20.9	51.7	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

CPIX institutional ownership history Ownership history

11.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	13	8	+62.5%
Opened positions	6	1	+500.0%
Closed positions	1	16	-93.8%
Increased positions	0	1	EXIT
Reduced positions	3	2	+50.0%

13F shares	Current	Prev Q	Change
Total value	1.88 bn	1.55 bn	+21.4%
Total shares	1.65 mm	1.20 mm	+38.0%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Renaissance Technologies	528.16 k	$676.05 mm	-1.9%
Vanguard	374.25 k	$479.04 mm	NEW
Dimensional Fund Advisors	284.01 k	$363.53 mm	-6.6%
Acadian Asset Management	188.16 k	$239.00 k	0.0%
BlackRock	110.07 k	$140.89 mm	NEW
BK The Bank of New York Mellon Corporation	75.27 k	$96.34 mm	0.0%
Geode Capital Management	74.31 k	$95.13 mm	-16.3%
NTRS Northern Trust	16.32 k	$20.89 mm	NEW
OAKC Oakworth Capital	3.05 k	$3.91 mm	0.0%
WFC Wells Fargo & Company	250.00	$320.00 k	NEW

Largest transactions	Shares	Bought/sold	Change
Vanguard	374.25 k	+374.25 k	NEW
BlackRock	110.07 k	+110.07 k	NEW
Dimensional Fund Advisors	284.01 k	-20.10 k	-6.6%
NTRS Northern Trust	16.32 k	+16.32 k	NEW
Geode Capital Management	74.31 k	-14.44 k	-16.3%
Renaissance Technologies	528.16 k	-10.00 k	-1.9%
Innealta Capital	0.00	-948.00	EXIT
WFC Wells Fargo & Company	250.00	+250.00	NEW
JPM JPMorgan Chase & Co.	219.00	+219.00	NEW
Advisor	100.00	+100.00	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CPIX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
28 Nov 25	Kazimi A J	Common Stock		Acquire L	No	Yes	2.41	18	43.38	5,700,885
28 Nov 25	Krogulski Kenneth	Common Stock		Acquire L	No	Yes	2.41	124	298.84	294,622
28 Nov 25	Jones James	Common Stock		Acquire L	No	Yes	2.41	18	43.38	44,793
28 Nov 25	Young Caroline	Common Stock		Acquire L	No	Yes	2.41	4	9.64	33,243
26 Nov 25	Kazimi A J	Common Stock		Acquire L	No	Yes	2.17	18	39.06	5,700,867
26 Nov 25	Krogulski Kenneth	Common Stock		Acquire L	No	Yes	2.17	124	269.08	294,498
26 Nov 25	Jones James	Common Stock		Acquire L	No	Yes	2.17	18	39.06	44,775
26 Nov 25	Young Caroline	Common Stock		Acquire L	No	Yes	2.17	4	8.68	33,239
25 Nov 25	Kazimi A J	Common Stock		Acquire L	No	Yes	2.21	18	39.78	5,700,849
25 Nov 25	Krogulski Kenneth	Common Stock		Acquire L	No	Yes	2.21	124	274.04	294,374

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Cumberland Q3 Adj. EPS $(0.06) Down From $(0.02) YoY, Sales $8.292M Down From $9.086M YoY

Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.06) per share. This is a 200 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $8.292 million in sales this

Earnings Scheduled For November 4, 2025

Cumberland To Co-Commercialize Talicia With RedHill, For The Treatment Of Helicobacter Pylori Infection In Adults, A Bacterial Infection And Leading Risk Factor For Gastric Cancer

Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapyNASHVILLE, Tenn., Oct. 20, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty

Cumberland Pharma Adds Potent Antibiotic, Vibativ, To National Group Purchasing Agreement With Premier

Cumberland Pharmaceuticals' Ibuprofen Injection Receives Mexican Regulatory Approval To Treat Pain And Fever; PiSA To Roll Out Product In Mexico

Press releases

From Benzinga Pro

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy NASHVILLE, Tenn., Oct. 20, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty

CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

Premier Membership includes 4,350 U.S. Hospitals NASHVILLE, Tenn., Oct. 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, has added their potent antibiotic,

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.